estim
healthrel
impact
pandem
influenza
isra
popul
use
rate
ill
physician
visit
hospit
death
deriv
previou
pandem
accord
meltzer
et
al
cost
relat
outcom
calcul
data
provid
major
isra
healthcar
organ
isra
central
bureau
statist
calcul
direct
cost
healthcar
system
overal
cost
economi
latter
includ
valu
lost
workday
potenti
valu
lost
live
point
estim
variabl
use
basecas
model
detail
tabl
appendix
accord
basecas
assumpt
pandem
would
result
estim
patient
isra
popul
physician
visit
hospit
death
lost
workday
outcom
would
result
excess
million
healthrel
cost
overal
cost
economi
million
isra
gross
domest
product
defin
strategi
use
antivir
drug
pandem
therapeut
use
longterm
preexposur
prophylaxi
shortterm
postexposur
prophylaxi
close
contact
influenza
patient
index
patient
treatment
first
strategi
could
target
either
entir
popul
high
risk
complic
efficaci
therapeut
treatment
base
current
avail
evid
regard
epidem
influenza
appendix
systemat
review
metaanalysi
use
estim
efficaci
preexposur
prophylaxi
expect
efficaci
postexposur
prophylaxi
number
person
treat
strategi
estim
use
result
recent
publish
stochast
simul
model
impact
strategi
healthrel
outcom
analyz
spreadsheet
model
use
formula
summar
figur
briefli
econom
benefit
strategi
calcul
multipli
reduct
advers
outcom
estim
econom
valu
cost
strategi
calcul
multipli
estim
number
treat
person
discount
cost
singl
antivir
cours
oseltamivir
select
drug
choic
daili
dosag
mg
prophylaxi
mg
treatment
oseltamivir
stockpil
cost
calcul
price
quot
march
manufactur
repres
israel
uncapsul
watersolubl
bulk
activ
powder
shelf
life
compar
econom
outcom
strategi
nonintervent
estim
stockpil
cost
calcul
costbenefit
ratio
base
histor
incid
influenza
pandem
last
centuri
adjust
costbenefit
outcom
conserv
estim
probabl
pandem
everi
year
appli
wide
rang
estim
sensit
analys
appendix
tabl
detail
costbenefit
ratio
compet
strategi
therapeut
treatment
postexposur
prophylaxi
shown
costsav
costbenefit
ratio
sinc
mani
characterist
next
pandem
viral
strain
remain
unknown
model
method
paramet
estim
design
consist
underestim
interventionrel
benefit
thu
yield
minimum
estim
true
costbenefit
ratio
seri
multivari
sensit
analys
use
variabl
rang
detail
tabl
model
prove
robust
even
unfavor
estim
prepandem
stockpil
remain
costsav
long
estim
probabl
pandem
remain
everi
year
consist
advantag
either
therapeut
shortterm
prophylact
use
antivir
drug
could
determin
light
recent
episod
human
infect
avian
influenza
world
health
organ
reiter
call
countri
prepar
next
inevit
possibl
immin
pandem
strainspecif
vaccin
effect
tool
influenza
control
like
avail
earli
stage
pandem
prolong
develop
time
earli
control
measur
employ
altern
option
mainli
judici
use
antivir
drug
drug
like
short
suppli
preemptiv
stockpil
compar
neuraminidas
inhibitor
drug
sever
major
disadvantag
mainli
high
rate
viral
resist
shown
recent
isol
advers
effect
model
suggest
prepandem
stockpil
oseltamivir
costsav
economi
wide
rang
treatment
strategi
stockpil
also
directli
costsav
healthcar
system
oseltamivir
use
limit
treat
patient
high
risk
invest
stockpil
remain
costsav
economi
long
estim
annual
pandem
risk
remain
pandem
everi
year
last
year
least
pandem
record
regardless
recent
event
southeast
asia
present
invest
antivir
agent
expect
yield
substanti
econom
return
per
invest
save
mani
live
favor
costbenefit
ratio
achiev
stockpil
antivir
drug
administ
either
sole
therapeut
measur
shortterm
prophylaxi
expos
contact
strategi
term
ring
prophylaxi
target
prophylaxi
studi
publish
date
use
dynam
mathemat
model
examin
expect
effect
latter
control
measur
popul
level
studi
suggest
strategi
may
significantli
reduc
ill
death
epidemiolog
direct
shortterm
prophylaxi
close
contact
may
requir
antivir
stockpil
consider
larger
necessari
therapeut
treat
patient
model
suggest
invest
may
still
prove
costsav
provid
outbreak
dissemin
pattern
popul
attribut
correl
assum
longini
et
al
appendix
one
consid
ring
prophylaxi
strategi
risk
strategi
failur
due
earli
antivir
stockpil
deplet
must
consid
postexposur
prophylaxi
confer
suffici
immun
upon
expos
contact
underw
prophylaxi
vaccin
addit
antivir
agent
becom
avail
rapid
consumpt
avail
stock
may
leav
popul
vulner
addit
outbreak
wave
potenti
caus
influx
new
case
probabl
similar
failur
scenario
difficult
assess
includ
analysi
applic
strategi
entir
popul
without
surplu
antivir
reserv
therefor
consid
cautious
monitor
close
studi
aim
elicit
minimum
costbenefit
estim
invest
nation
antivir
stockpil
among
conserv
assumpt
chose
exclud
indirect
cost
prevent
death
ad
would
increas
costbenefit
ratio
appendix
furthermor
view
recent
event
east
asia
probabl
pandem
probabl
risen
per
year
new
strain
may
prove
pathogen
previou
pandem
strain
model
benefit
therapeut
strategi
omit
benefici
effect
decreas
viral
shed
afford
neuraminidas
inhibitor
lower
secondari
attack
rate
among
untreat
contact
also
ignor
possibl
fulli
implement
prophylact
strategi
might
achiev
full
contain
outbreak
probabl
estim
postexposur
ring
prophylaxi
depend
sever
factor
complianc
delay
treatment
initi
basic
reproduct
number
final
wit
epidem
sever
acut
respiratori
syndrom
sar
econom
consequ
rapidli
dissemin
diseas
extend
well
beyond
direct
cost
healthcar
system
lost
workday
canada
loss
billion
sar
epidem
although
diseas
directli
affect
patient
econom
viewpoint
mitig
pandem
could
prevent
extens
indirect
econom
loss
conclus
studi
must
consid
care
plan
antivir
stockpil
drug
price
expect
chang
substanti
result
contractu
negoti
manufactur
although
result
indic
stockpil
may
remain
costsav
even
drug
cost
tripl
would
case
preprepar
capsul
purchas
powderform
antivir
drug
consider
advantag
term
cost
shelf
life
logist
aspect
prepar
distribut
assess
confirm
feasibl
final
assum
strainspecif
vaccin
would
avail
suffici
quantiti
first
stage
pandem
effort
current
direct
toward
shorten
delay
avail
strainspecif
vaccin
would
like
favor
intervent
antivir
agent
serv
adjunct
treatment
summari
prepandem
stockpil
antivir
drug
expect
prove
costsav
costbenefici
strategi
use
may
involv
treatment
patient
back
adequ
antivir
stockpil
shortterm
postexposur
prophylaxi
close
contact
strategi
consid
plan
stockpil
effort
sever
countri
alreadi
begun
activ
stockpil
effort
suffici
case
allow
antivir
treatment
popul
believ
antivir
stockpil
consid
prudent
invest
may
help
mitig
impend
global
threat
use
static
spreadsheet
model
microsoft
excel
microsoft
corpor
redmond
wa
usa
estim
effect
pandem
influenza
isra
popul
defin
separ
strategi
use
antivir
drug
pandem
analyz
effect
strategi
pandem
outcom
estim
econom
consequ
scenario
divid
popul
israel
end
age
categori
year
year
year
age
categori
group
low
highrisk
seriou
complic
influenza
infect
use
us
popul
agespecif
proport
adjust
age
structur
isra
popul
highrisk
group
number
person
total
popul
point
estim
rang
healthrel
variabl
use
basecas
model
detail
tabl
construct
baselin
nonintervent
scenario
use
age
riskspecif
rate
estim
expect
number
patient
physician
visit
hospit
death
lost
work
day
calcul
econom
valu
outcom
outcom
recalcul
intervent
strategi
describ
detail
yield
econom
benefit
associ
strategi
result
figur
compar
cost
associ
purchas
enough
antivir
stock
implement
strategi
econom
outcom
point
estim
econom
variabl
use
basecas
model
detail
tabl
cost
patient
visit
includ
cost
prescript
drug
diagnost
test
base
current
data
provid
major
healthcar
organ
israel
hospit
workday
cost
provid
isra
central
bureau
statist
benefit
strategi
defin
cost
save
yield
rel
nonintervent
calcul
direct
cost
healthcar
system
overal
cost
economi
latter
includ
valu
lost
workday
indirect
cost
excess
death
accord
previou
assess
meltzer
et
al
address
similar
scenario
valu
live
lost
made
estim
cost
pandem
influenza
appli
estim
studi
addit
valu
live
lost
increas
calcul
costbenefit
ratio
drug
resist
may
appear
approxim
one
third
patient
treat
inhibitor
amantadin
rimantadin
earli
rimantadin
resist
describ
drug
use
treatment
postexposur
prophylaxi
famili
vitro
suscept
test
recent
human
isol
east
asia
indic
strain
resist
antivir
drug
amantadin
rimantadin
suscept
neuraminidas
inhibitor
oseltamivir
furthermor
oseltamivir
shown
effect
virus
mice
inhibitor
sever
major
disadvantag
includ
higher
rate
advers
effect
proven
efficaci
reduc
influenza
complic
rate
current
avail
neuraminidas
inhibitor
oseltamivir
zanamivir
oseltamivir
licens
prophylaxi
israel
unit
kingdom
unit
state
therefor
limit
analysi
oseltamivir
daili
dose
mg
use
prophylaxi
mg
use
treatment
per
diem
oseltamivir
cost
calcul
strategi
use
project
number
neuraminidas
inhibitor
recipi
drug
price
quot
march
manufactur
repres
israel
roch
pharmaceut
israel
ltd
per
comm
paramet
relat
drug
cost
detail
tabl
base
calcul
shelf
life
drug
store
bulk
activ
powder
discount
perform
use
local
accept
annual
rate
costbenefit
ratio
strategi
calcul
divid
strategyspecif
drug
cost
treatmentderiv
econom
benefit
ratio
calcul
separ
direct
healthrel
cost
overal
cost
economi
sinc
differ
strategi
mutual
exclus
increment
costbenefit
analysi
perform
adjust
costbenefit
outcom
estim
probabl
pandem
occur
per
year
base
calcul
recent
histor
incid
influenza
pandem
last
centuri
thu
adopt
conserv
point
estim
pandem
everi
year
basecas
appli
wide
rang
estim
sensit
analys
baselin
scenario
model
use
estim
deriv
meltzer
et
al
previou
pandem
data
collect
israel
interpandem
period
provid
estim
healthrel
econom
outcom
would
expect
pandem
allow
run
natur
cours
estim
meltzer
et
al
base
wide
rang
possibl
attack
rate
ill
death
rate
estim
consider
lower
estim
pathogen
potenti
current
circul
avian
strain
estim
select
line
gener
approach
underestim
pandem
effect
potenti
benefit
provid
intervent
explain
paramet
use
calcul
detail
tabl
formula
detail
figur
scenario
serv
refer
categori
altern
strategi
compar
given
therapeut
influenza
patient
within
hour
symptom
onset
continu
day
neuraminidas
inhibitor
reduc
durat
clinic
symptom
averag
day
hospit
rate
antimicrobi
drug
use
tabl
sinc
effect
treatment
reduc
death
rate
yet
studi
quantifi
includ
model
yetunproven
potenti
benefit
drug
keep
approach
toward
underestim
benefit
intervent
moreov
effect
death
rate
reduct
would
alter
costbenefit
calcul
sinc
illnessrel
cost
taken
account
evalu
variat
therapeut
antivir
use
nonselect
treatment
avail
patient
strategi
select
treatment
limit
use
patient
high
risk
strategi
adjust
model
treatment
initi
rate
sinc
patient
would
expect
reach
physician
initi
treatment
within
window
therapeut
opportun
proport
patient
like
seek
physician
care
estim
use
data
avail
studi
interpandem
influenza
israel
wide
rang
estim
use
sensit
analysi
address
treatmentseek
behavior
crisi
evalu
variat
preexposur
antivir
use
mass
prophylaxi
made
avail
entir
popul
strategi
select
prophylaxi
limit
group
increas
risk
complic
strategi
assum
pandem
durat
day
calcul
drug
cost
accordingli
perform
systemat
review
metaanalysi
studi
evalu
protect
efficaci
neuraminidas
inhibitor
use
preexposur
season
prophylaxi
method
result
metaanalysi
describ
computer
search
conduct
use
medlin
januari
embas
januari
databas
follow
combin
keyword
use
influenza
oseltamivir
tamiflu
zanamivir
relenza
prevent
prophylaxi
chemoprophylaxi
search
limit
articl
publish
english
addit
search
databas
use
name
author
studi
identifi
primari
search
studi
refer
section
also
contact
drug
compani
inform
unpublish
trial
search
identifi
candid
paper
paper
independ
review
author
rdb
ig
blind
author
name
journal
date
public
site
studi
candid
paper
select
random
control
doubleblind
trial
met
follow
criteria
evalu
preexposur
season
prevent
natur
occur
influenza
zanamivir
oseltamivir
oseltamivir
mgday
zanamivir
mgday
includ
studi
sampl
whose
particip
year
age
includ
healthi
communitybas
popul
without
specif
baselin
diseas
provid
data
intenttotreat
analysi
report
incid
laboratoryconfirm
influenza
placebo
control
group
two
studi
met
inclus
criteria
tabl
summar
main
featur
studi
includ
analysi
author
review
paper
also
abstract
inform
select
studi
case
articl
publish
studi
articl
assess
data
consist
data
abstract
use
standard
protocol
computer
report
form
report
rel
risk
rr
incid
data
necessari
comput
rr
abstract
base
intenttotreat
analysi
studi
includ
analysi
case
defin
clinic
influenza
confirm
isol
influenza
viru
reversetranscriptas
polymeras
chain
reaction
rtpcr
test
pair
serum
sampl
rise
antibodi
titer
circul
influenza
viru
studi
calcul
rr
confid
interv
ci
influenza
infect
intervent
group
compar
control
group
calcul
overal
rr
preexposur
prophylaxi
sinc
oseltamivir
zanamivir
neuraminidas
inhibitor
result
studi
evalu
drug
compar
combin
result
studi
overal
estim
studi
ci
rr
calcul
use
breslow
method
sinc
result
individu
studi
homogen
overal
rr
ci
calcul
use
precisionbas
estim
describ
fleiss
kleinbaum
et
al
assum
homogen
effect
studi
fixedeffect
model
protect
efficaci
intervent
calcul
rr
heterogen
rr
across
n
studi
test
formula
mi
individu
measur
associ
wi
weight
factor
equal
reciproc
squar
individu
varianc
signific
evalu
n
degre
freedom
sinc
studi
preexposur
prophylaxi
includ
sensit
analysi
appli
comput
perform
use
pepi
softwar
epidemiolog
analysi
result
studi
overal
estim
preexposur
studi
present
tabl
overal
protect
efficaci
intervent
ci
result
use
point
estim
protect
efficaci
neuraminidas
inhibitor
use
set
preexposur
prophylaxi
tabl
scenario
stockpil
antivir
agent
administ
shortterm
prophylaxi
expos
close
contact
addit
treat
index
patient
strategi
term
ring
prophylaxi
target
prophylaxi
strategi
studi
publish
date
use
dynam
mathemat
model
examin
expect
effect
pandem
control
measur
popul
level
pandem
stochast
simul
model
longini
et
al
suggest
influenza
pandem
postexposur
prophylaxi
target
close
contact
ie
household
daycar
center
play
group
school
might
prevent
infect
provid
prophylact
antivir
cours
popul
adopt
result
point
estim
allow
wide
rang
valu
sensit
analysi
tabl
estim
one
publish
date
efficaci
strategi
influenza
pandem
inher
limit
stochast
model
one
use
longini
et
al
must
acknowledg
strategi
consid
practic
author
studi
model
commun
peopl
predefin
mix
pattern
subpopul
rel
limit
number
outsid
enter
popul
pauciti
evidencebas
data
contact
transmiss
probabl
regard
epidem
pandem
influenza
well
complex
reallif
mix
pattern
within
larg
popul
may
lead
substanti
alter
efficaci
target
prophylaxi
model
longini
et
al
shown
estim
sensit
variou
current
unpredict
paramet
popul
pandem
strain
popul
complianc
delay
treatment
initi
outbreak
basic
reproduct
number
addit
strategi
requir
rel
rapid
use
larg
antivir
stock
may
potenti
lead
prematur
deplet
stockpil
postexposur
prophylaxi
strategi
less
like
lead
earli
deplet
antivir
stock
use
first
stage
pandem
long
rel
suspect
case
identifi
first
stage
longer
prophylact
cours
may
consid
scale
outbreak
increas
applic
strategi
becom
problemat
may
lead
rapid
consumpt
stockpil
drug
therefor
monitor
close
strategi
clinic
influenza
would
develop
vari
proport
particip
receiv
prophylaxi
despit
treatment
breakthrough
case
assum
patient
although
becom
ill
would
nonetheless
benefit
neuraminidas
inhibitor
receiv
credit
effect
therapeut
neuraminidas
inhibitor
treatment
shorter
durat
ill
fewer
hospit
death
see
strategi
littl
evidencebas
data
current
avail
allow
accur
predict
regard
effect
next
influenza
pandem
model
well
similar
publish
model
attempt
make
infer
regard
impend
pandem
base
estim
deriv
mainli
spars
data
previou
pandem
characterist
interpandem
influenza
systemat
chosen
conserv
estim
avail
literatur
regard
differ
paramet
estim
still
associ
much
uncertainti
seri
sensit
analys
therefor
conduct
establish
robust
variou
outcom
model
analys
appli
wide
rang
valu
paramet
relat
pandem
probabl
healthrel
pandem
outcom
antivir
drug
efficaci
consid
econom
paramet
rel
stabl
base
verifi
data
tabl
list
variabl
use
strategi
outcom
estim
rang
use
sensit
analys
sensit
analysi
examin
effect
modif
paramet
main
outcom
costbenefit
ratio
thu
assess
variabl
model
sensit
analysi
show
import
paramet
sever
pandem
ill
death
rate
annual
probabl
pandem
reduc
annual
probabl
pandem
everi
year
strategi
treat
patient
high
risk
repres
cost
save
costbenefit
ratio
combin
lowrang
estim
accord
meltzer
et
al
variou
healthrel
pandem
outcom
model
assum
costbenefit
ratio
therapeut
treatment
postexposur
prophylaxi
decreas
strategi
remain
costsav
costbenefit
ratio
respect
analyz
data
defin
rang
costbenefit
ratio
appli
variou
combin
paramet
tabl
result
analys
present
tabl
assum
annual
pandem
probabl
per
year
togeth
unfavor
set
estim
paramet
intervent
strategi
becom
howev
annual
probabl
pandem
remain
everi
year
stockpil
antivir
drug
treat
patient
high
risk
remain
consist
costsav
even
one
assum
unfavor
set
estim
within
rang
appli
paramet
sinc
current
event
southeast
asia
suggest
probabl
pandem
may
time
greater
upper
limit
everi
year
costbenefit
ratio
adjust
multipli
current
highend
estim
factor
addit
healthrel
effect
pandem
may
similar
wors
seen
higher
attack
rate
complic
rate
hospit
death
rate
exampl
assum
highend
attack
rate
rate
physician
visit
hospit
doubl
upper
valu
costbenefit
ratio
therapeut
treatment
patient
postexposur
prophylaxi
would
respect
pursu
higher
rang
valu
basic
conclus
regard
costbenefit
current
purchas
antivir
drug
chang
